siRNA SPECIFIC TO TBCE GENE OR CITED2 GENE AND ITS USE

PROBLEM TO BE SOLVED: To provide siRNA capable of exhibiting effect of an anticancer platinum complexes also to cancer cell exhibiting resistance to the complexes. SOLUTION: Double-stranded siRNA is a double-stranded siRNA of 21 bases composed of 19 pairs of bases and 3' terminal overhang of 2...

Full description

Saved in:
Bibliographic Details
Main Authors YANAGIMORI HIRONOBU, ERIGUCHI MASAZUMI, HISA SATOYUKI
Format Patent
LanguageEnglish
Published 25.10.2007
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
COMPOSITIONS THEREOF
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROCESSES OF PREPARING SUCH COMPOSITIONS
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:PROBLEM TO BE SOLVED: To provide siRNA capable of exhibiting effect of an anticancer platinum complexes also to cancer cell exhibiting resistance to the complexes. SOLUTION: Double-stranded siRNA is a double-stranded siRNA of 21 bases composed of 19 pairs of bases and 3' terminal overhang of 2 bases, in which sequence of the 19 pair of bases has a specific sequence, and targeting TBCE (tublin specific chaperone E) gene or CITED2 (CBP/P300-interacting transactivator) gene. Anticancer action of the complexes can be improved even in cancer cell exhibiting resistance to the complexes by combinedly using the double-stranded siRNA with the anticancer platinum complexes. COPYRIGHT: (C)2008,JPO&INPIT
Bibliography:Application Number: JP20070025859